MedDataX Logo

Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)

NCT ID: NCT01390792

Last Updated: 2017-05-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

622 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relenza® Sentinel Site Monitoring Program in Japan

NCT01199744

Influenza, Human
COMPLETED

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

NCT01231620

Influenza, Human
COMPLETED PHASE3

Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study

NCT01353768

Infections, Respiratory Tract
COMPLETED

Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults

NCT01314911

Influenza, Human
COMPLETED NA

Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

NCT01014988

Influenza, Human
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza, Human

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects prescribed zanamivir

Subjects prescribed zanamivir during study period

Zanamivir hydrate

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zanamivir hydrate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who meet the study population criteria

Exclusion Criteria

* Subjects with a history of hypersensitivity to the ingredients of zanamivir
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

References

Explore related publications, articles, or registry entries linked to this study.

Keizo Matsumoto, Hideyuki Okano, Naomi Hasegawa, Ichiro Ohwaki, Shogo Inoshiri. Study on Preventive Effects of Zanamivir (Relenza) for Influenza. Medicine and Drug Journal. 2010;46(11):121-132.

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

112316

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical Evaluation of QFlu Combo Test
NCT01506583 COMPLETED
Oseltamivir Randomised Controlled Efficacy Trial
NCT00707941 COMPLETED PHASE3
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
NCT00957996 COMPLETED PHASE3
Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir
NCT00799760 TERMINATED PHASE3
A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza
NCT02603952 COMPLETED PHASE1/PHASE2
Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
NCT00419263 COMPLETED PHASE2
A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection
NCT02293863 COMPLETED PHASE2
Early Oseltamivir Treatment of Influenza in Children 1-3 Years of Age
NCT00593502 COMPLETED PHASE4
Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir
NCT00980109 COMPLETED PHASE4
A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects
NCT00540501 WITHDRAWN PHASE1
A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection
NCT02532283 COMPLETED PHASE2
Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications
NCT01227967 COMPLETED PHASE2
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
NCT01527110 COMPLETED PHASE3
Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
NCT00610935 TERMINATED PHASE3
Early Oseltamivir Carboxylate Low Plasma Concentration in Patients Admitted to Intensive Care for Severe Influenza
NCT05375864 UNKNOWN NA
A Study of Intravenously Administered Tamiflu (Oseltamivir) in Patients Over 13 Years of Age With Influenza
NCT01050257 COMPLETED PHASE3
A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model
NCT01980966 COMPLETED PHASE2
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
NCT04539262 COMPLETED PHASE1/PHASE2
Zanamivir Versus Trivalent Split Virus Influenza Vaccine
NCT00784784 COMPLETED PHASE3
Safety and Dose Study of Peramivir for Influenza Treatment
NCT00297050 COMPLETED PHASE1
Prophylactic Treatment With Oseltamivir
NCT03899571 COMPLETED NA
Study Evaluating the Efficacy and Safety of AV5080 in Patients With Uncomplicated Influenza
NCT05093998 UNKNOWN PHASE3
Efficacy and Safety of Combination Therapies With Oseltamivir & Zanamivir or Oseltamivir & Amantadine Versus Oseltamivir Monotherapy in the Treatment of Seasonal Influenza A Infection
NCT00830323 TERMINATED PHASE2
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain
NCT01032837 TERMINATED PHASE4
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
NCT03605862 COMPLETED PHASE3